Taysha Gene Therapies, Inc. (TSHA)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Revenue | 1,986 | 2,302 | 1,788 | |
| Impairment of long-lived assets | - | - | 4,838 | |
| Research and development | 20,141 | 15,565 | 14,946 | |
| General and administrative | 8,598 | 8,158 | 7,902 | |
| Total operating expenses | 28,739 | 23,723 | 27,686 | |
| Loss from operations | -26,753 | -21,421 | -25,898 | |
| Other (expense) income | -237 | 13 | -81 | |
| Interest income | 1,859 | 1,326 | 2,107 | |
| Interest expense | 17 | 19 | 24 | |
| Change in fair value of warrant liability | 273 | -102 | -75 | |
| Change in fair value of term loan | 1,461 | 1,530 | 1,703 | |
| Total other (expense) income, net | -129 | -108 | 374 | |
| Net loss | -26,882 | -21,529 | -25,524 | |
| Earnings per share, basic, total | -0.09 | -0.08 | -0.1 | |
| Earnings per share, diluted, total | -0.09 | -0.08 | -0.1 | |
| Weighted average number of shares outstanding, basic, total | 297,988,978 | 269,306,331 | 267,824,045 | |
| Weighted average number of shares outstanding, diluted, total | 297,988,978 | 269,306,331 | 267,824,045 | |